{
    "clinical_study": {
        "@rank": "50336", 
        "arm_group": {
            "arm_group_label": "ARTRA", 
            "description": "Patients with low back pain treated with ARTRA."
        }, 
        "brief_summary": {
            "textblock": "To study the safety and efficacy of ARTRA (glucosamine chondroitin sulfate) in the treatment\n      of non-specific low-back pain of lumbosacral localization in ambulatory care."
        }, 
        "brief_title": "Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Chronic Low Back Pain", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Low Back Pain", 
        "condition_browse": {
            "mesh_term": [
                "Back Pain", 
                "Low Back Pain"
            ]
        }, 
        "detailed_description": {
            "textblock": "We enrolled patients between 40 and 65 years of age who had low back pain for at least 12\n      weeks with a pain intensity >3 on a 0-10 point visual analogue scale (VAS).  Major exclusion\n      criteria were presence of fibromyalgia, degenerative spondylolisthesis, and alcohol and/or\n      drug abuse.  All patients were treated with ARTRA (combination of glucosamine hydrochloride\n      500 mg and chondroitin sulfate 500 mg in tab; Unipharm Inc.) at a dose of 1 tab bid for the\n      first month and then 1 tab daily for the next two months.  The primary endpoint was pain\n      intensity (at rest and movement) as measured on a 0-10 point VAS.  Secondary endpoints\n      included Oswestry Disability Index, patient global assessment of efficacy (0-5 scale) and\n      NSAID consumption."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients aged 40-65 years, inclusively.\n\n          2. Pain intensity according to Visual Analogue Scale (VAS) > 3 points.\n\n          3. Duration of back pain > 12 weeks.\n\n          4. Pain reinforcement during movement in lumbar spine.\n\n          5. Osteoarthritis, spondylarthrosis, osteochondrosis.\n\n          6. Given written Informed consent form for participation in the study.\n\n          7. Treatment with ARTRA\n\n        Exclusion Criteria:\n\n          1. History of allergic reactions to chondroprotectors.\n\n          2. Participation in another clinical study within 30 days before screening or during\n             this study.\n\n          3. Fibromyalgia.\n\n          4. Active neoplastic disease, history of neoplastic disease within 3 years before\n             screening.\n\n          5. Paget's disease.\n\n          6. Degenerative spondylolisthesis.\n\n          7. Administration of anticonvulsant, antidepressant, barbiturate, anxiolytic, or muscle\n             relaxant drugs for more than one week prior screening.\n\n          8. History of alcohol or drug abuse.\n\n          9. Frequent episodes of nausea, dyspepsia, pain in the epigastric region, diarrhea, face\n             and extremities edema, dizziness and headache.\n\n         10. History of any disease that, in the opinion of the investigator, might confound the\n             results of the study or poses an additional risk to the subject during participation\n             in the study\n\n         11. Clinically significant renal disorders.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic low back pain in ambulatory care"
            }
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990729", 
            "org_study_id": "ARTRA-PMS-LBP/2012"
        }, 
        "intervention": {
            "arm_group_label": "ARTRA", 
            "description": "ARTRA (glucosamine and chondroitin sulfate)", 
            "intervention_name": "ARTRA", 
            "intervention_type": "Dietary Supplement", 
            "other_name": [
                "Glucosamine", 
                "Chondroitin sulfate"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Hydroquinone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation"
                }, 
                "name": "FGBU \"State NII of Rheumatology\" of RAMS"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Non-specific Chronic Low Back Pain of Lumbosacral Localization in Ambulatory Care", 
        "overall_official": {
            "affiliation": "Irish Clinical Outcomes in Research and Education", 
            "last_name": "Gurkirpal Singh, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pain intensity on Visual Analogue Scale", 
            "measure": "Pain Intensity", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990729"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Oswestry Disability Index", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Patient global assessment of efficacy", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Number of patients taking NSAIDs", 
                "measure": "NSAID consumption", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Unipharm, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Unipharm, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}